The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

We are thrilled to have John join the Nurix team as we prepare to launch our pivotal clinical program for NX-5948 in chronic lymphocytic leukemia and potentially other B-cell malignancies,” said ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...

SAN FRANCISCO - Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in targeted protein modulation drugs, announced today the appointment of John Northcott as its new ...

Here are 10 healthcare industry lawsuits, settlements and legal developments that Becker's has reported since Jan. 14: ...

Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

The United States market has experienced a notable upswing, climbing by 3.8% over the past week and achieving a 24% increase over the last year, with earnings forecasted to grow by 15% annually. In ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

It’s always a good sign when a couple of big deals are announced right before the conference, and this year we saw a doozie ...

Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that ...

Development and commercialisation of diagnostic and therapeutic radiopharmaceuticals.